OBJECTIVE: To analyze the clinical and psychometric properties of observational gait assessment scales in people with neurological disorders. DATA SOURCES: The databases used for the literature search were MEDLINE, the Cochrane Central Register of Controlled Trial, Web of Science, and the Cumulative Index to Nursing and Allied Health. The search was conducted between September 15 and November 30, 2014. STUDY SELECTION: Studies that investigate and validate observational gait assessment scales in people with central nervous system disorders. DATA EXTRACTION: General characteristics of the studies, including number of patients and observational gait assessment scales analyzed and their psychometric properties, were extracted. DATA SYNTHESIS: After the literature search, 15 articles were included in this review. Seven of the 15 articles studied the Tinetti Gait Scale (TGS), 2 studied the Rivermead Visual Gait Assessment (RVGA), 1 studied the Gait Assessment and Intervention Tool (G.A.I.T.), 3 studied the Wisconsin Gait Scale, and one of them compared the TGS and the G.A.I.T. CONCLUSIONS: The scale that appears to be the most suitable for both clinical practice and research is the G.A.I.T. because it has shown to be valid, reliable, and sensitive to change, homogeneous, and comprehensive, containing a large number of items that assess most components of the gait pattern. The RVGA was studied in those with diverse neurological disorders, including multiple sclerosis. For those with Parkinson disease, the TGS showed sensitivity and the Tinetti Performance-Oriented Mobility Assessment (POMA) showed predictive capability for falls and mortality as well as intra- and interrater reliability. The Tinetti POMA was also studied in those with normal pressure hydrocephalus, showing sensitivity and in those with Huntington disease, showing reliability and validity. More research is needed to more comprehensively analyze the psychometric properties of the RVGA, Wisconsin Gait Scale, TGS, and G.A.I.T. in patients with diverse neurological disorders, other than stroke.
OBJECTIVE: To analyze the clinical and psychometric properties of observational gait assessment scales in people with neurological disorders. DATA SOURCES: The databases used for the literature search were MEDLINE, the Cochrane Central Register of Controlled Trial, Web of Science, and the Cumulative Index to Nursing and Allied Health. The search was conducted between September 15 and November 30, 2014. STUDY SELECTION: Studies that investigate and validate observational gait assessment scales in people with central nervous system disorders. DATA EXTRACTION: General characteristics of the studies, including number of patients and observational gait assessment scales analyzed and their psychometric properties, were extracted. DATA SYNTHESIS: After the literature search, 15 articles were included in this review. Seven of the 15 articles studied the Tinetti Gait Scale (TGS), 2 studied the Rivermead Visual Gait Assessment (RVGA), 1 studied the Gait Assessment and Intervention Tool (G.A.I.T.), 3 studied the Wisconsin Gait Scale, and one of them compared the TGS and the G.A.I.T. CONCLUSIONS: The scale that appears to be the most suitable for both clinical practice and research is the G.A.I.T. because it has shown to be valid, reliable, and sensitive to change, homogeneous, and comprehensive, containing a large number of items that assess most components of the gait pattern. The RVGA was studied in those with diverse neurological disorders, including multiple sclerosis. For those with Parkinson disease, the TGS showed sensitivity and the Tinetti Performance-Oriented Mobility Assessment (POMA) showed predictive capability for falls and mortality as well as intra- and interrater reliability. The Tinetti POMA was also studied in those with normal pressure hydrocephalus, showing sensitivity and in those with Huntington disease, showing reliability and validity. More research is needed to more comprehensively analyze the psychometric properties of the RVGA, Wisconsin Gait Scale, TGS, and G.A.I.T. in patients with diverse neurological disorders, other than stroke.
Authors: Alberto Ferrari; David Milletti; Pierpaolo Palumbo; Giulia Giannini; Sabina Cevoli; Elena Magelli; Luca Albini-Riccioli; Paolo Mantovani; Pietro Cortelli; Lorenzo Chiari; Giorgio Palandri Journal: Fluids Barriers CNS Date: 2022-06-23
Authors: Francisco Molina-Rueda; Pilar Fernández-González; Alicia Cuesta-Gómez; Aikaterini Koutsou; María Carratalá-Tejada; Juan Carlos Miangolarra-Page Journal: Int J Environ Res Public Health Date: 2021-02-02 Impact factor: 3.390
Authors: Cecilia Estrada-Barranco; Vanesa Abuín-Porras; Javier López-Ruiz; Ismael Sanz-Esteban; Francisco Molina-Rueda; Roberto Cano-de-la-Cuerda Journal: Int J Environ Res Public Health Date: 2021-06-27 Impact factor: 3.390
Authors: G Puyuelo-Quintana; R Cano-de-la-Cuerda; A Plaza-Flores; E Garces-Castellote; D Sanz-Merodio; A Goñi-Arana; J Marín-Ojea; E García-Armada Journal: J Neuroeng Rehabil Date: 2020-05-06 Impact factor: 4.262
Authors: Francesco Negrini; Giulio Gasperini; Eleonora Guanziroli; Jacopo Antonino Vitale; Giuseppe Banfi; Franco Molteni Journal: Int J Environ Res Public Health Date: 2020-05-02 Impact factor: 3.390